Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.

Health-EpiGEICAM WCRF/AICR guidelines breast cancer cancer prevention recommendations compliance health behaviours healthy lifestyle lifestyle recommendations survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Sep 2022
Historique:
received: 09 09 2022
accepted: 23 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potentially associated clinical and sociodemographic factors. A total of 420 BC survivors, aged 31-80, was recruited from 16 Spanish hospitals. Epidemiological, dietary and physical activity information was collected through questionnaires. A 7-item score to measure compliance with the recommendations was built according to the 2018 WCRF/AICR scoring criteria. Standardized prevalences and standardized prevalence ratios of moderate and high compliance across participant characteristics were estimated using multinomial and binary logistic regression models. The mean score was 3.9 (SD: 1.0) out of 7 points. Recommendations with the worst adherence were those of limiting consumption of red/processed meats (12% of compliance, 95% CI: 8.2-15.0) and high fibre intake (22% of compliance, 95% CI: 17.6-27.0), while the best compliance was observed for the consumption of fruits and vegetables (73% of compliance, 95% CI: 69.2-77.7). Overall, adherence was worse in women with university education and in those with first-degree relatives with BC. This information may be of interest to design and implement personalized preventive measures adapted to the characteristics of these patients.

Identifiants

pubmed: 36230628
pii: cancers14194705
doi: 10.3390/cancers14194705
pmc: PMC9561971
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fundación Científica Asociación Española Contra el Cancer
ID : AECC 2016

Références

Cancers (Basel). 2021 Oct 23;13(21):
pubmed: 34771493
Int J Environ Res Public Health. 2019 Apr 15;16(8):
pubmed: 30991645
Nutrients. 2020 Feb 26;12(3):
pubmed: 32110887
Fam Cancer. 2007;6(3):287-94
pubmed: 17429760
Ann Oncol. 2020 Mar;31(3):352-368
pubmed: 32067678
J Clin Epidemiol. 2007 Sep;60(9):874-82
pubmed: 17689803
Nutrients. 2019 Jul 12;11(7):
pubmed: 31336836
Breast. 2019 Apr;44:144-152
pubmed: 30780085
J Hum Nutr Diet. 2011 Apr;24(2):128-34
pubmed: 21332835
Br J Cancer. 2014 Sep 23;111(7):1454-62
pubmed: 25101568
Obes Rev. 2011 Apr;12(4):282-94
pubmed: 20880127
BMC Med. 2019 Dec 2;17(1):221
pubmed: 31787099
Br J Nutr. 2022 Mar 28;127(6):927-938
pubmed: 33988098
Support Care Cancer. 2019 Dec;27(12):4565-4574
pubmed: 30927111
Br J Nutr. 2017 Mar;117(5):737-749
pubmed: 28366183
J Cancer Surviv. 2019 Apr;13(2):257-268
pubmed: 30982113
Br J Nutr. 2021 May 28;125(10):1188-1200
pubmed: 33087189
J Gen Intern Med. 2014 Jul;29(7):1060-4
pubmed: 24452418
Clin Nutr. 2021 Apr;40(4):1537-1545
pubmed: 33743289
Nutrients. 2019 Jul 03;11(7):
pubmed: 31277273
Mayo Clin Proc. 2019 Nov;94(11):2178-2188
pubmed: 31623843
Nutr J. 2013 Feb 19;12:26
pubmed: 23421854
Gynecol Oncol. 2017 Mar;144(3):577-585
pubmed: 28057355
BMJ Open. 2018 Feb 19;8(2):e014530
pubmed: 29459359
Eur J Nutr. 2019 Oct;58(7):2875-2886
pubmed: 30284064
Am J Epidemiol. 2004 Aug 15;160(4):301-5
pubmed: 15286014
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1153-61
pubmed: 23576689
Br J Nutr. 2019 Mar;121(5):481-495
pubmed: 30630543
J Clin Oncol. 2008 May 1;26(13):2198-204
pubmed: 18445845
Cancer Causes Control. 2016 Nov;27(11):1303-1314
pubmed: 27644127
Support Care Cancer. 2017 Aug;25(8):2581-2591
pubmed: 28303381
Brain Behav Immun. 2022 Jan;99:307-316
pubmed: 34673177
J Cancer Surviv. 2010 Jun;4(2):119-27
pubmed: 20180037
Nutr Cancer. 2021;73(9):1570-1580
pubmed: 32795218
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):889-894
pubmed: 32152215
J Ga Public Health Assoc. 2016 Fall;6(2 Suppl):210-222
pubmed: 28066830
Integr Cancer Ther. 2014 Mar;13(2):114-20
pubmed: 24105362
Nutrients. 2017 Mar 25;9(4):
pubmed: 28346353
Nutr J. 2011 Oct 25;10:118
pubmed: 22027238
Adicciones. 2022 Feb 16;34(1):61-72
pubmed: 32677700
Breast Cancer Res Treat. 2020 Aug;182(3):727-738
pubmed: 32535764
PLoS One. 2015 May 15;10(5):e0126096
pubmed: 25978407
Int J Cancer. 2016 Jan 1;138(1):237-44
pubmed: 26175188
Sci Rep. 2017 Apr 4;7(1):599
pubmed: 28377568
Cancer Treat Rev. 2012 Apr;38(2):152-63
pubmed: 21612873
Clin Pharmacol Ther. 2011 Jul;90(1):164-8
pubmed: 21633341
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Cancer Surviv. 2019 Jun;13(3):327-343
pubmed: 30993648
BMJ. 2018 Feb 14;360:k322
pubmed: 29444771
Front Oncol. 2019 Jan 22;9:3
pubmed: 30723698
Nutrients. 2020 Jul 13;12(7):
pubmed: 32668662

Auteurs

Virginia Lope (V)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

Angel Guerrero-Zotano (A)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Instituto Valenciano Oncología, 46006 Valencia, Spain.

Emma Ruiz-Moreno (E)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Begoña Bermejo (B)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Clínico de Valencia, Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.
Medical Unit, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, 28029 Madrid, Spain.
Medicine Department, Universidad de Valencia, 46010 Valencia, Spain.

Silvia Antolín (S)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Complejo Hospitalario Universitario A Coruña -CHUAC, 15006 A Coruña, Spain.

Álvaro Montaño (Á)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.

José Manuel Baena-Cañada (JM)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Puerta del Mar, Instituto de Investigación e Innovación Biomédica de Cádiz (INIBICA), 11009 Cádiz, Spain.

Manuel Ramos Vázquez (M)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Centro Oncológico de Galicia, 15009 A Coruña, Spain.

Nerea Fernández de Larrea-Baz (N)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

José Ignacio Chacón (JI)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain.

José Angel García-Sáenz (JA)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Unit, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, 28029 Madrid, Spain.
Medical Oncology, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.

Clara Olier (C)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital de Alcorcón, 28922 Madrid, Spain.

Montserrat Muñoz (M)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Clinic i Provincial i IDIBAPS, 08036 Barcelona, Spain.

Antonio Antón (A)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.

Pedro Sánchez Rovira (P)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Universitario de Jaén, 23007 Jaén, Spain.

Angels Arcusa Lanza (A)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Consorci Sanitari de Terrassa, 08227 Terrassa, Spain.

Sonia González (S)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Mutua Terrassa, 08221 Terrassa, Spain.

Amparo Oltra (A)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Virgen de los Lirios, 03804 Alicante, Spain.

Joan Brunet (J)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Institut Català d'Oncologia, Hospital Josep Trueta, Oncogir, IDIBGI, 17007 Girona, Spain.

Joaquín Gavilá Gregori (J)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Instituto Valenciano Oncología, 46006 Valencia, Spain.

María Teresa Martínez (MT)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Hospital Clínico de Valencia, Biomedical Research Institute INCLIVA, 46010 Valencia, Spain.

Lourdes Calvo (L)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Oncology, Complejo Hospitalario Universitario A Coruña -CHUAC, 15006 A Coruña, Spain.

Libertad Rosell (L)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

Susana Bezares (S)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

Roberto Pastor-Barriuso (R)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Beatriz Pérez-Gómez (B)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

Miguel Martín (M)

GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.
Medical Unit, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, 28029 Madrid, Spain.
Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.

Marina Pollán (M)

Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Avda. Monforte de Lemos 5, 28029 Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
GEICAM Spanish Breast Cancer Group, Scientific Department, 28703 Madrid, Spain.

Classifications MeSH